Results 31 to 40 of about 32,786 (220)
Nonchemotherapy Treatment of Immunoglobulin Light Chain Amyloidosis
Acta Haematologica, 2020 Immunoglobulin light chain amyloidosis (AL amyloidosis) is a rare, life-threatening disease characterized by the deposition of misfolded proteins in vital organs such as the heart, the lungs, the kidneys, the peripheral nervous system, and the ...
Layla N. Van Doren, S. Lentzsch
semanticscholar +3 more sources
Light Chain Stabilization: A Therapeutic Approach to Ameliorate AL Amyloidosis
Hemato, 2021 Non-native immunoglobulin light chain conformations, including aggregates, appear to cause light chain amyloidosis pathology. Despite significant progress in pharmacological eradication of the neoplastic plasma cells that secrete these light chains, in ...
Gareth J. Morgan +2 more
doaj +2 more sources
Differences in immunoglobulin light chain species found in urinary exosomes in light chain amyloidosis (Al). [PDF]
PLoS ONE, 2012 Renal involvement is a frequent consequence of plasma cell dyscrasias. The most common entities are light chain amyloidosis, monoclonal immunoglobulin deposition disease and myeloma cast nephropathy.
Marina Ramirez-Alvarado +7 more
doaj +2 more sources
Cutaneous light chain amyloidosis with multiple myeloma: A concise review
Hematology/Oncology and Stem Cell Therapy, 2019 Objective/Background: Cutaneous immunoglobulin (Ig) amyloid light-chain (AL) amyloidosis associated with overt multiple myeloma (MM) is rare and optimal treatment is not well defined.
Mirela Andrei, Jen Chin Wang
doaj +2 more sources
Journal of Medical Case Reports, 2010 Introduction Refractory pleural effusion in systemic immunoglobulin light chain amyloidosis without cardiac decompensation is rarely reported and has a poor prognosis in general (a median survival of 1.6 months).
Mima Akira +13 more
doaj +2 more sources
Risk factors for venous thromboembolism in immunoglobulin light chain amyloidosis
Haematologica, 2016 Patients with immunoglobulin light chain amyloidosis are at risk for both thrombotic and bleeding complications. While the hemostatic defects have been extensively studied, less is known about thrombotic complications in this disease.
Fangui Sun +8 more
core +4 more sources
The challenge of systemic immunoglobulin light-chain amyloidosis (Al)
, 2012 The cardiac involvement and associated mortality that occur in systemic AL amyloidosis remain among the most challenging aspects of the systemic amyloid-related diseases.
Giovanni Palladini +3 more
core +4 more sources
Novel targeted therapies for immunoglobulin light chain amyloidosis: latest updates from the 2024 ASH annual meeting [PDF]
Journal of Hematology and OncologyHong-Hu Zhu +2 more
exaly +2 more sources
Immunoglobulin light chain amyloidosis: 2022 update on diagnosis, prognosis, and treatment
American journal of hematology/oncology, 2022 Immunoglobulin light chain amyloidosis is a clonal, nonproliferative plasma cell disorder in which fragments of immunoglobulin light or heavy chain are deposited in tissues.
M. Gertz
semanticscholar +1 more source
Current Opinion in Chemical Biology, 2023 Immunoglobulin light chain amyloidosis (AL) is a cancer of plasma cells that secrete unstable full-length immunoglobulin light chains. These light chains misfold and aggregate, sometimes with aberrant endoproteolysis, leading to organ toxicity.
N. Yan +4 more
semanticscholar +1 more source